Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies

Table 2 HR values of OS and DFS of NSCLC subgroups

	Outcome	Studies (n)	Patients	HR	95%CI	P value	Model	H, I², P value
OS	All study	28	4534	1.58	1.33-1.87	0.000	Random	100.02,74.0 %,0.000
	Asian	14	2729	1.97	1.43-2.71	0.000	Random	72.62,82.1 %,0.000
	Non-Asian	14	2278	1.37	1.15-1.64	0.013	Random	22.99,74.0 %,0.000
	Stage I	8	1144	1.85	1.27-2.69	0.001	Random	32.90,78.7 %,0.000
	Stage I-II	8	1166	1.72	1.20-2.46	0.003	Random	29.43,76.2 %,0.000
	Stage I-III	7	1038	1.60	1.21-2.12	0.001	Fixed	9.44, 36.5 %,0.150
	Stage III-IV	1	58	1.31	0.68-2.53	0.42	Fixed	-
	ADC	10	1327	2.21	1.38-3.50	0.000	Random	64.38,86.0 %,0.000
	Asian	6	666	3.01	1.96-4.02	0.000	Random	8.70,42.5 %,0.122
	Non-Asian	4	661	1.31	0.74-2.33	0.359	Random	18.38,83.7 %,0.000
	Stage I-II	6	446	3.30	1.37-7.96	0.008	Random	45.94,89.1 %,0.000
	Stage I-III/IV	4	881	1.51	0.92-2.47	0.102	Random	7.75,761.3 %,0.051
	Non-ADC	2	184	1.88	0.88-4.01	0.105	Fixed	-
DFS	All study	8	1326	2.21	1.43-3.43	0.000	Random	28.35,75.3 %,0.000
	Asian	5	591	2.78	1.78-4.34	0.000	Random	4.67,14.4 %,0.323
	Non-Asian	3	735	1.83	1.09-3.06	0.022	Random	48.95,77.7 %,0.01
	Stage I	3	293	4.31	2.37-7.84	0.000	Fixed	0.79,0.0 %,0.672
	Stage I-II	2	265	1.51	1.02-2.23	0.038	Fixed	0.48,0.0 %,0.486
	Stage I-III/IV	3	783	2.02	0.97-4.20	0.06	Random	11.69, 82.9 %, 0.0.06

Abbreviation: ADC adenocarcinoma, CI confidence interval, DFS disease-free survival, Fixed, Fixed, Inverse Variance model, H Heterogeneity, HR hazard ratio, I² I-squared, OS overall survival, Random, Random, I-V heterogeneity model

ISSN: 1471-2407